Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Overview of the imaging biomarker roadmap

Published byDarren Oliver Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Overview of the imaging biomarker roadmap"— Presentation transcript:

1 Figure 1 Overview of the imaging biomarker roadmap
Figure 1 | Overview of the imaging biomarker roadmap. Imaging biomarkers must cross translational gap 1 to become robust medical research tools, and translational gap 2 to be integrated into routine patient care. This goal is achieved through three parallel tracks of technical (assay) validation, biological and clinical validation, and cost effectiveness. O’Connor, J. P. B. et al. (2016) Imaging biomarker roadmap for cancer studies Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 1 Overview of the imaging biomarker roadmap"

Similar presentations

Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Management of personal care needs

Figure 4 Management of personal care needs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google